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Manuscript 
ABSTRACT 
Aldosterone treatment of M1-CCD cells stimulated an increase in epithelial Na+ 
channel (ENaC) -subunit expression that was mainly localized to the apical 
membrane. PKD1 suppressed cells constitutively expressed ENaCat low 
abundance, with no increase after aldosterone treatment. Here ENaCwas mainly 
localized proximal to the basolateral surface of the epithelium both before and after 
aldosterone treatment. Apical membrane insertion of ENaCin response to 
aldosterone treatment was also sensitive to PKD1 suppression as was the 
aldosterone-induced rise in the amiloride-sensitive, trans-epithelial current (ITE). The 
interaction of the mineralocorticoid receptor (MR) with specific elements in the 
promoters of aldosterone responsive genes is stabilized by ligand interaction and 
phosphorylation. PKD1 suppression inhibited aldosterone-induced SGK-1 
expression. The nuclear localization of MR was also blocked by PKD1 suppression 
and MEK antagonism implicating both these kinases in MR nuclear stabilization. 
PKD1 thus modulates aldosterone-induced ENaC activity through the modulation of 
sub-cellular trafficking and the stabilization of MR nuclear localization. 
Key words: Aldosterone, ENaC, Protein kinase D, Renal, Cortical collecting duct, 
Hypertension. 
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INTRODUCTION 
The steroid hormone aldosterone is a key regulator of electrolyte transport and blood 
pressure that acts upon multiple tissues and organ systems in the in the body, where 
its specific mineralocorticoid receptor (MR) is expressed; such target sites include the 
distal nephron of the kidney, the distal colon, the heart and the vascular endothelium. 
The principal effect of aldosterone action in renal and colonic epithelia is in the 
regulation of membrane transport molecules, such as the epithelial sodium channel 
(ENaC). ENaC activity plays a crucial role in the maintenance of whole body Na+ 
homeostasis (1, 2); the abundance of ENaC along the aldosterone-sensitive distal 
nephron (ASDN), coupled with channel trafficking into the apical membrane of the 
epithelial cells facilitates and determines the rate of Na+ re-absorption from the renal 
ultra-filtrate. The release of aldosterone as the last phase of the renin/ angiotensin 
cascade maintains tight hormonal control over ENaC expression and membrane 
insertion. Fully active ENaC is a heterotrimer composed of one each of the -, - and 
-subunits (3). Aldosterone regulates ENaC activity through multiple, synergistic 
mechanisms. For example, MR in complex with aldosterone acts as a liganddependent 
transcription factor that stimulates the tissue–specific transcriptional upregulation 
of ENaC subunits in the distal nephron (and in the lung); it is the ENaC
subunit that is under the direct transcriptional control of ligand-bound MR, while 
ENaCand ENaCare constitutively expressed or else only weakly induced by 
aldosterone (4). ENaC activity is also subject to indirect genomic regulation by 
aldosterone through increasing the stability and half-life of pre-expressed ENaC 
subunits. Aldosterone suppresses the proteasomic degradation of ENaC through the 
serum glucocorticoid stimulated kinase (SGK-1)-dependent suppression of the 
ubiquitination of ENaC subunits by the E3 ubiquitin-protein ligase, Nedd4-2 (5, 6). 
Aldosterone also up-regulates the expression of a ubiquitin-specific protease USP2- 
45 to de-ubiquitinate and further stabilize pre-expressed ENaC subunits (7). 
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The most rapid reported increase in amiloride-sensitive, ENaC current was detected 
in isolated principal cortical collecting duct (CCD) cells 2 min after aldosterone 
treatment (8); the signalling cascade responsible for increased ENaC activity in this 
model remains unknown. Other experimental systems may provide a clue as to the 
mechanism behind this rapid increase in ENaC activity; such as the elevation of 
apical membrane ENaC density that is coupled to the stimulation of RhoA-mediated 
vesicle trafficking (9). The modulation of the rates of membrane insertion and subcellular 
trafficking may thus be important additional mechanisms for ENaC regulation 
by aldosterone (10). While the increase in ENaC activity following aldosterone 
treatment is more typically detected several hours after hormone treatment and is 
associated with the direct and indirect transcriptional effects through MR; rapidly 
activated signalling cascades may serve to potentiate or amplify these effects. The 
rapid activation of signalling cascades by aldosterone in cells of renal origin has been 
described by numerous groups [reviewed in (11)], and these rapid responses have 
variously been described as MR-dependent or MR-independent [reviewed in (12)]. 
The role of aldosterone-induced rapid signalling responses in modulating the key 
physiological responses to aldosterone such as renal Na+ re-absorption or K+ 
secretion is still unclear. 
We recently demonstrated that aldosterone stimulated the activation of protein kinase 
D (PKD)1 in the M1-CCD cell line through an EGFR-coupled signalling cascade that 
was initiated by the interaction of aldosterone with MR (13). PKD1 is the prototypic 
member of the PKD family of serine/ threonine protein kinases, and is activated in 
response to diverse extra-cellular stimuli (14) to regulate crucial cellular processes 
including cell growth and apoptosis [reviewed in (15)]. Each of the PKD family 
isoforms have also been implicated in different aspects of the regulation of subcellular 
trafficking, either through the maintenance of Golgi structure or by regulating 
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TGN fission and Golgi to membrane vesicle trafficking through the activation of PI4KIII 
(16-18). The RhoA-mediated translocation of ENaC to the cell membrane is 
coupled to vesicle trafficking through the activation of PI4P5K (9). Interestingly, the 
ENaC subunits are also known to interact directly with phosphatidylinositide 
signalling intermediates (19), and PKD1 itself can be activated as a consequence of 
stimulating RhoA-coupled signalling cascades (20). We have shown that PKD1 
activation by aldosterone in M1-CCD cells played a role in early, sub-cellular 
trafficking events that resulted in the redistribution of eCFP-tagged ENaC subunits 
within a few minutes of aldosterone treatment (21). These findings are advanced in 
this present study through the investigation the role of aldosterone-induced PKD1 
activation in regulating aldosterone-induced ENaC activity, and the sub-cellular 
distribution of ENaC subunits in M1-CCD cells. The time frame analysed in this 
present study is coincident with detectable increases in ENaC-dependent transepithelial 
electrical current (ITE), and we found that suppression of PKD1 expression 
inhibited both the apical translocation of ENaC subunits and the increase in 
amiloride-sensitive ITE stimulated by aldosterone treatment. 
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MATERIALS AND METHODS 
Cell culture and reagents 
The M1-CCD cell line (ATCC, CRL-2038) was derived from renal CCD microdissected 
from a mouse transgenic for the early region of SV40 virus (strain 
Tg(SV40E) Bri7) (22). M1-CCD cells were routinely grown in 75 cm2 polystyrene 
culture flasks containing 1:1 Dulbecco’s modified Eagle’s medium and Ham’s F-12 
medium (DMEM:F-12) with fetal bovine serum (10%); supplemented with L-glutamine 
(2 mM), penicillin (100 units.ml-1), streptomycin (100 g.ml-1) and dexamethasone (5 
M). Cultures were maintained in an atmosphere of 70% humidity, 5% CO2 at 37oC. 
Culture medium was changed every 2 to 3 days, and cells were sub-cultured by 
trypsinization before they became confluent. For experimental purposes, M1-CCD 
cells were propagated on 13 mm diameter Millicell-HA semi-permeable supports 
(Millipore), in 8-well glass chamber slides (Nunc) or 10 cm dia. culture dishes as 
required; experiments were performed once a fully confluent monolayer had been 
established. Aldosterone (Steraloids) was prepared as a 50 mM stock in ethanol; 
then further diluted in culture medium, so that the final concentration was 10 nM. 
Vehicle controls were the equivalent concentration of ethanol diluted in culture 
medium. All other chemical reagents used in this investigation were purchased from 
Sigma-Aldrich, unless otherwise indicated. 
Development of PKD1 siRNA knock-down cell line 
An M1-CCD cell line was developed that stably expressed a PKD1-specific siRNA as 
previously described (21). Briefly, oligonucleotides were designed to facilitate the 
synthesis of DNA expression cassettes that expressed PKD1-specific siRNA 
molecules, under the control of the murine U6 promoter using the Silencer Express 
system (Ambion). The efficacy of each of the expression cassettes in suppressing 
PKD1 expression was verified by Western blotting using a PKD1 specific antibody. 
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Expression cassettes that effectively suppressed PKD1 expression were sub-cloned 
between the EcoR1 and Hind III sites of the pSEC-neo mammalian expression vector 
(Ambion). Recombinant plasmids were transfected into M1-CCD cells using 
Lipofectamine 2000 (Invitrogen). Neomycin resistant clones harbouring the plasmid 
developed into colonies following propagation in the presence of G418, and were 
isolated (21). Cell numbers were amplified in selective medium, and all experiments 
using the PKD1 stable knock down cell line were performed in the presence of G418. 
Continued suppression of PKD1 expression in the knockdown cell line was verified 
by Western blotting using the PKD1-specific antibody. 
Confocal immunofluorescence imaging 
M1-CCD cells were grown on 13 mm cover slips until a confluent monolayer was 
established. After treatment with aldosterone as indicated; the cell monolayer was 
washed in ice-cold PBS and fixed in 4% paraformaldehyde in PBS. The cell 
membranes were disrupted in 0.2% Triton X-100 in TBS, and the non-specific 
binding of antibodies and fluorescent conjugates were blocked by incubation in 2% 
gelatin as above. Specific rabbit polyclonal antibodies were used to detect ENaC
(Chemicon) and ENaC(Abcam); MR was detected using a specific murine mAb, 
MRN 4E4 (23). Bound primary antibodies were detected using a goat anti-mouse 
Alexa488 conjugate (Invitrogen), or a goat anti-rabbit Alexa488 conjugate (Invitrogen) 
as appropriate. Cells were counter stained with TRITC labelled phalloidin for the 
detection of polymerized actin, or with Alexa 546 labelled wheat germ agglutinin 
(WGA) for detection of the cell membrane as indicated. Labelling of the cell 
membrane with Alexa546-WGA was performed in advance of cell membrane 
disruption, in order to stain the apical membrane only. Cells were mounted in 
Vectashield (Vector Laboratories) containing 4’,6-diamidino-2-phenylindole (DAPI), 
and examined using a LSM 510 Meta confocal microscope. Laser excitation 
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wavelengths for DAPI Alexa Fluor 488 Alexa 546 and TRITC were 361 nm, 488 nm 
543 nm and 543 nm respectively. Images were captured at x 40 magnification and 
x4 zoom. Scans were performed at 1m interval depths through the fixed cells, and 
single or merged images are presented as XY single planes through the mid-section 
of the cells unless otherwise specified. Determination of ENaCmembrane insertion 
was captured at x63 magnification; XZ planes show apical to basolateral crosssections 
of the labelled cell monolayers. 
Trans-epithelial current measurements 
Wild-type M1-CCD cells and M1-CCD cells suppressed in PKD1 expression were 
seeded at a density of 1 x105 cells per well onto 0.6 cm semi-permeable supports, 
and maintained in DMEM:F12 medium supplemented as above. The medium was 
changed every 48 h after seeding and the trans-epithelial resistance (RTE) of the 
developing monolayer was measured daily, using an EVOM (World Precision 
Instruments) Ohmeter connected to STX electrodes. The RTE of wild-type and PKD1 
suppressed M1-CCD cells were compared over 7 days. The development of a high 
resistance epithelium, as determined by changes in RTE by the M1-CCD cells, was 
not significantly affected by PKD1 suppression. Once high resistance had been 
established (>1 k), the culture medium was substituted with serum free medium 
containing 1 M dexamethasone for 6 h, this did not significantly affect RTE. The 
epithelial monolayers were subjected to antagonist and hormone treatments for the 
times indicated. RTE; trans-epithelial potential difference (VTE) measurements were 
recorded, and ITE was calculated using Ohm’s law (VTE /ITE = RTE). The experiment 
was repeated 3 times and the data shown are from one representative experiment, 
expressed as mean ITE S.E.M. measurements of n= 8 separate cell monolayers at 
each time point with ITE values expressed as A/cm2. 
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Preparation of cell lysates and sub-cellular fractions 
For experimental purposes, wild-type M1-CCD and PKD1 suppressed M1-CCD cells 
were seeded into 10 cm dishes, grown to 80% confluency and a quiescent state was 
induced through growth in serum free medium for 24 h. Cells were incubated with 
aldosterone (10 nM) or vehicle control for periods indicated. Following treatment, the 
cell monolayers were washed three times with ice cold PBS and collected in 1 ml 
PBS. To obtain cell lysates, cell suspensions were centrifuged at 4oC for 30 s at 2000 
xg and the supernatant was removed. The cell pellet was lysed with the addition of 
lysis buffer (20 mM Tris-HCl pH 7.6, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 1 mM 
of dithiothreitol, 10 μg.ml-1 aprotinin, 10 μg.ml-1 leupeptin, 10 mM NaF, 1 mM 
phenylmethylsufonylfluoride and 0.5% v/v NP40). Insoluble material was isolated by 
centrifugation at 4oC for 15 min at 20 000 xg. For nuclear/ cytoplasmic sub-cellular 
fractionation, isolated cells were re-suspended in extraction buffer A (1.5 mM MgCl2, 
10 mM KCl, 0.5 mM DTT, 10mM HEPES, pH 7.9) and centrifuged at 20 000 xg for 10 
min. The pellets were resuspended in a further 50 l buffer A that was supplemented 
with IGEPAL (0.1%), centrifuged as above and the supernatant containing the 
cytoplasmic proteins was isolated. The insoluble material was combined with 50 l 
extraction buffer B (420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25 % Glicerol, 
20 mM HEPES pH 7.9) and re-suspended by vigorous vortexing before 
centrifugation as above. The supernatant from this second lysis step comprised the 
nuclear fraction. The protein concentration of each of the lysates was determined and 
standardized by Bradford Assay (Bio-Rad). 
SDS-PAGE and Western blotting 
Cell lysates were dissolved by boiling in Laemmli sample buffer and proteins were 
separated by SDS-PAGE on 10% w/v polyacrylamide gels. The proteins were 
transferred onto PVDF membranes, and probed with the specified primary antibodies 
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diluted in 5% w/v bovine serum albumin (BSA) in TBS according to the supplier’s 
instructions. Bound antibodies were detected using anti-mouse or anti-rabbit 
horseradish peroxidase secondary conjugates; antibody-labeled proteins were 
visualized by enhanced chemiluminescence, ECL (Amersham Biosciences). 
Exposed films were digitally photographed and subjected to densitometric analysis 
using GeneSnap software (Synoptics). ENaC sub unit antibodies and the MR-specific 
antibody were as above. The SGK-1 antibody and laminin antibody were obtained 
from Santa Cruz Biotechnology and Cell Signalling respectively. The -actin 
antibody, anti-mouse and anti rabbit IgG horseradish peroxidase secondary 
conjugates were obtained from Sigma-Aldrich. 
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RESULTS 
Aldosterone-induced ENaCsubunit expression in M1-CCD cells is PKD1- 
dependent 
ENaC activity is subject to regulation by aldosterone through different mechanisms 
including the transcriptional regulation of subunit expression, and the modulation of 
subunit ubiquitination; which affects ENaC abundance at sub-apical, cytoplasmic 
pools. These inactive pools of ENaC can be recruited to the apical membrane in 
response to specific agonists and the activation of their associated secondary 
messenger systems (9). We have previously shown that aldosterone treatment 
stimulates the rapid sub-cellular redistribution of pre-expressed, eCFP-tagged ENaC 
subunits (21). In this present study, the effect of aldosterone treatment over more 
extended periods on the sub-cellular localization and abundance of ENaCwas 
investigated by immunofluorescence in order to lend greater physiological relevance 
to our original findings. This experimental approach also allowed a differentiated, 
confluent epithelium of M1-CCD cells to be used as an experimental model, and 
avoided the physiological consequences of constitutive ENaC subunit overexpression 
when using heterologous expression plasmids. In untreated M1-CCD 
cells, ENaCwas present in the cytoplasm at barely detectable levels (Fig. 1A); 
while after 24 h aldosterone treatment the ENaCsubunit increased in expression 
relative to the untreated control. Here ENaC was detected as punctuate 
immunofluorescent staining of the cytoplasm, suggesting the localization of ENaC to 
distinct cytoplasmic vesicles. ENaC was also abundant in the confocal XY plane 
above the perijunctional filamentous actin ring, suggesting that a sub-set of the 
ENaCwas localized to sites proximal to the apical membrane. Conversely, there 
was no ENaCimmuno-staining in the most basolateral XY confocal plane, 
suggesting a lack of ENaCin this region of the epithelial cells. 
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We have previously demonstrated that PKD1 is significantly activated (3-fold above 
basal levels) in aldosterone treated M1-CCD cells (13), and that PKD1 activation is 
also involved in the rapid translocation of ENaC subunits observed within 2 min of 
aldosterone treatment in the M1-CCD cells (21). The elucidation of the role of PKD1 
in these aldosterone responses was facilitated by deriving a M1-CCD cell line clone 
that stably expressed a PKD1-specific siRNA, and which achieved 80-90% 
suppression of PKD1 protein expression. In this cell line ENaCwas expressed at a 
higher basal level of abundance than was observed in the wild-type cells (Fig. 1). In 
addition, after 24 h aldosterone treatment, ENaCabundance was not altered in the 
PKD1 suppressed cells and ENaCremained localized to densely staining sites in 
the cytoplasm, which were basolateral relative to the perijunctional filamentous actin 
ring. The increase in ENaCabundance after aldosterone treatment was thus 
dependent on PKD1 expression and activation, as was the association of ENaC with 
the apical membrane (Fig. 1B). These data suggest a dual role for PKD1 in the 
regulation of ENaC activity by aldosterone through the modulation of MR-dependent 
gene expression, and also through the modulation of sub-cellular trafficking. 
Membrane insertion of ENaC is PKD1-dependent 
The increase in ENaC abundance in the cell membrane following aldosterone 
treatment is the product of a combination of processes that influence ENaC subunit 
expression, stability and trafficking. Recent investigations have implicated each of the 
PKD isoforms in the regulation of vesicle fission from the TGN to facilitate Golgi to 
cell membrane trafficking (24). Consequently, the insertion of ENaC into the cell 
membrane following aldosterone treatment may be influenced by the rate of post- 
Golgi vesicle fission that is regulated by the PKD family proteins. In order to 
distinguish the effects of PKD1 activation on ENaC subunit trafficking as opposed to 
the gene expression effects, ENaCmembrane insertion was investigated by 
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immuno-fluorescence before and after 24 h aldosterone treatment. The ENaC
subunit is not subject to transcriptional control by aldosterone in the distal nephron in 
the manner of ENaC, and allows some discrimination to be made between the dual 
effects of PKD1 activation. The apical membrane of the cells making up the intact, 
confluent M1-CCD cell monolayer was labelled using Alexa546 conjugated to WGA; 
the tight junction complexes of live, confluent, epithelial cells prevent access of the 
complex to sub-apical membranes when staining is performed prior to fixation, 
resulting in staining of the apical membrane only. We observed that in wild-type cells 
ENaCwas located in the cytoplasm with greater basolateral localization, and no 
colocalization 
with the WGA, suggesting low apical membrane abundance (Fig. 2). 
However, following aldosterone treatment for 24 h, there was a diminished 
basolateral localization of ENaCand increased insertion of ENaCinto the apical 
membrane as indicated by WGA co-localization. In the PKD1 suppressed cells, 
ENaCwas localized to the cytoplasm and there was no increase in apical 
membrane abundance following aldosterone treatment for 24 h. The pattern of 
localization of ENaCin the cytoplasm without aldosterone treatment also differed 
between the wild-type and knock-down cells. ENaCexpressed by wild-type cells 
was localized to densely staining, punctate structures within the cytoplasm; while the 
ENaCexpressed by PKD1 suppressed cells was evenly distributed through the 
cytoplasm of the cells. These data demonstrate that PKD1 expression influenced the 
distribution of ENaCto vesicular structures in advance of aldosterone treatment, 
and also determines the apical membrane insertion of ENaC subunits following 
aldosterone treatment. 
Aldosterone stimulation of the amiloride-sensitive ITE is PKD1-dependent 
PKD1 activation is implicated in post-Golgi protein trafficking, and the establishment 
of a high RTE by epithelial cells is dependent upon the secretion of occlusion junction 
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proteins into the intercellular space. Suppression of PKD1 expression may be 
anticipated to have a deleterious effect on the establishment of high RTE by a 
monolayer of M1-CCD cells through the perturbation of protein trafficking. To 
investigate this possibility, M1-CCD cells and cells suppressed in PKD1 expression 
were seeded onto semi-permeable supports, and the RTE was measured and 
recorded daily over the course of 7 days (Fig. 3A). The data is presented SEM and 
was obtained by measuring RTE of four individual monolayers for each cell line, and is 
representative of three independent experiments carried out on different days. Wildtype 
cells developed maximum electrical resistance (1.38 0.12 k) 7 d after 
seeding; when seeded at an identical density (1 x 105 per well) the PKD1 suppressed 
cells developed maximum electrical resistance (1.63 0.08 k) 6 d after seeding. 
The RTE of wild-type and PKD suppressed cells was not significantly different, and 
the RTE remained stable for 3 to 4 d after the RTE maxima were reached. 
M1-CCD cells develop high RTE that is equivalent to that measured for the primary 
CCD making them a suitable model for investigating the physiology of the CCD, and 
in particular the effects of aldosterone (25). Aldosterone stimulates an amiloridesensitive 
increase in ENaC current in M1-CCD cells 2 to 4 h after treatment (25) and 
we found that in the presence of 1 M dexamethasone, wild-type M1-CCD cells and 
M1-CCD cells suppressed in PKD1 expression had a basal ITE of 5 A/cm2 (Fig. 3B). 
However, following aldosterone treatment, the wild-type cells generated a significant 
rise in ITE, increasing to 6 A/cm2 after 2 h, which further increased to 10 A/cm2 4 h 
after aldosterone treatment. This increase in ITE was stable and sustained for at least 
24 h after hormone treatment, when the ITE was measured at 11 A/cm2 and 
amiloride treatment caused the ITE to rapidly drop back to 4 A/cm2. Thus basal 
ENaC activity contributed a current of 1 A/cm2 to the total ITE that increased to a 7 
A/cm2 contribution 24 h after aldosterone treatment. In comparison aldosterone 
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stimulated a small increase in ITE in the PKD1 suppressed cells, which was maximal 
after 4 h at 7 A/cm2 as compared to 10 A/cm2 for the wild-type cells over the 4 to 
24 h time period. This increase in ITE at 4h by the PKD1-suppressed cells was not 
sustained, and the amiloride-sensitive component of the stimulated ITE was 2 A/cm2 
as compared to 7 A/cm2 for the wild-type cells. These data demonstrate that 
aldosterone stimulates a 7-fold increase in the amiloride-sensitive, ENaC component 
of the total ITE in the M1-CCD cells that is greatly attenuated when the expression of 
PKD1 is suppressed. 
The stimulation of an ENaC current in the M1-CCD cells was only detectable when 
the cells were treated with aldosterone in combination with dexamethasone. 
Aldosterone treatment alone did not stimulate a detectable change in ITE and it has 
been noted by other workers that M1-CCD cells grown in the absence of 
dexamethasone fail to develop a high RTE when propagated on semi-permeable 
supports. The measured elevation of ENaC activity in the M1-CCD cells therefore, 
requires concurrent MR and glucocorticoid receptor (GR) stimulation. Aldosterone 
alone can activate GR, but this is proposed to occur only at super-physiological 
concentrations of the hormone. The requirement for dexamethasone co-treatment in 
order to achieve the establishment of a high RTE and a detectable ENaC current 
following aldosterone treatment in this study confirms that the aldosterone-induced 
effects on ENaC are mediated by MR and not by GR. However, the effects of 
aldosterone on ENaC activity can only be detected on a glucocorticoid-replete 
background. 
Aldosterone-induced MR translocation is PKD1-dependent 
The stimulation of ENaC activity by aldosterone over extended periods of hormone 
treatment is the product of the transcriptional up-regulation of ENaC subunits, 
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particularly ENaCin the distal nephron, and also the up-regulation of proteins that 
regulate ENaC abundance in the cell membrane such as SGK-1. Aldosterone 
stimulates the translocation of pre-expressed ENaC subunits (21); while full channel 
activity requires expression of all three subunits, and ENaCexpression in unstimulated 
M1-CCD cells is extremely low. Any effect of aldosterone on ENaC 
membrane abundance through the modulation of sub-cellular trafficking requires that 
the expression of ENaC subunits first to be induced. Consequently, there is a lag 
between hormone treatment and a change in membrane abundance, with a resulting 
increase in aldosterone sensitive ITE. In addition to its role in modulating sub-cellular 
vesicle movement, PKD1 also regulates transcriptional response through its 
interaction with IB kinase (IKK) (26) and ERK1/2 mitogen activated protein (MAP) 
kinase (27). It is well established that the modulation of gene expression by 
aldosterone is largely through the stabilization of the interaction of MR with target 
DNA sequences to promote transcription. 
The change in the sub-cellular distribution of MR in M1-CCD cells treated with 
aldosterone was investigated using immuno-fluorescent detection with a MR-specific 
antibody (Fig. 4). In this present study we found that aldosterone treatment not only 
enhanced the association of MR with the nucleus, but also promoted the 
translocation of MR to discrete cytoplasmic sites proximal to the nucleus within 2 min 
of treatment. The increased localization of oestrogen receptor with the cell nucleus 
following oestrogen treatment is dependent on phosphorylation of the receptor by 
ERK1/2 MAP kinase (28); while the involvement of ERK1/2 in enhancing the 
association of MR with the nucleus following aldosterone treatment has not 
previously been described. PKD1 stabilizes the activation of ERK1/2 in response to 
G-protein coupled receptor agonists (27), and the modulation of ERK1/2 activity may 
be one mechanism by which PKD1 can affect the redistribution of MR following 
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aldosterone treatment. We found that this increase in MR abundance at the nucleus 
following aldosterone treatment, was sensitive to antagonism of the MEK/ERK 
cascade with PD98059 and was also inhibited in PKD1 suppressed M1-CCD cells. 
The synergistic actions of ERK1/2 and PKD1 thus converge to facilitate the subcellular 
redistribution of MR that precedes aldosterone-induced changes in gene 
expression. 
After 30 min treatment with aldosterone, a time frame when the transcriptional effects 
of MR first become detectable; MR in the wild-type cells was largely localized to the 
perinuclear region of the cytoplasm, with some punctate staining of the nucleus (Fig. 
5). In PKD1 suppressed cells, the MR was localized mainly in the cell cytoplasm, with 
some nuclear and perinuclear staining evident. This distribution was maintained after 
60 min aldosterone treatment; however, after 120 min treatment in wild-type M1-CCD 
cells, MR was localized to one or two discrete accumulations adjacent to the nucleus 
with granular staining of the nucleus itself. In the PKD1 suppressed cells, MR was 
uniformly distributed throughout the cell cytoplasm with very little nuclear staining and 
no punctate perinuclear staining. Antagonism of the MEK/ERK cascade with 
PD98059 completely inhibited the aldosterone-induced perinuclear localization of MR 
30 min after hormone treatment (Fig. 6). Sub-cellular fractionation experiments were 
performed on M1-CCD cells and M1-CCD cells suppressed in PKD1 expression with 
and without aldosterone treatment to confirm the role of PKD1 in MR nuclear 
localization (Fig. 7). Treatment of wild-type cells with aldosterone resulted in an 
increase in the nuclear abundance of MR within 5 min, which peaked around 30 min 
and declined to basal levels after 60 min. The redistribution of MR in response to 
ligand 5 min and 30 min after aldosterone treatment was sensitive to MEK 
antagonism with PD98059. PKD1-suppression resulted in attenuation of the MR 
redistribution in response to aldosterone treatment. Taken together, these 
observations confirmed that the sub-cellular redistribution of MR in response to 
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aldosterone, at a time point relevant to the modulation of transcription by 
aldosterone, was dependent on activation of the MEK/ERK cascade and PKD1 
activity. 
PKD1 involvement in aldosterone-induced gene expression 
MR modulates the expression of many genes in response to aldosterone treatment. 
The most rapidly detected change in gene transcription following aldosterone 
treatment is that of SGK-1; where changes in abundance of SGK-1 mRNA can be 
detected within 20 min, and changes in SGK-1 protein abundance can be detected 
within 1 h of aldosterone treatment. We previously investigated whether PKD1 
suppression could affect the early transcriptional response to aldosterone in the M1- 
CCD cells, and found that there was no significant effect on the induction of SGK-1 
expression by aldosterone after 30 min treatment (21). In this present study we found 
that aldosterone elicited a diminished increase in ENaC current 4 h after hormone 
treatment in cells that were suppressed in PKD1 expression as compared to wildtype. 
Consequently we examined the effect of PKD1 suppression on the induction of 
SGK-1 protein expression 4 h after aldosterone treatment. We found that SGK-1 
expression was barely detectable by Western blotting in both the wild-type and PKD1 
suppressed M1-CCD cells without stimulation (Fig. 8A). However, 4 h after 
aldosterone treatment there was a significant increase in detectable SGK-1 protein. 
The increase in SGK-1 abundance was 5 to 6-fold in the wild-type cells as compared 
to 2-fold in the PKD1 suppressed cells; indicating that the loss of PKD1 expression 
significantly attenuated the long term effects of MR activation by aldosterone on 
target gene expression. 
The abundance of the ENaCsubunit is not regulated through transcription by 
aldosterone in the cells of the distal nephron, and as expected, aldosterone treatment 
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did not significantly affect ENaCprotein abundance in either wild-type or PKD1 
suppressed M1-CCD cells (Fig. 8B), in addition the abundance of ENaCin the two 
cell lines before aldosterone treatment also did not differ significantly. PKD1 
suppression also did not affect the total abundance of MR in M1-CCD cells, as 
indicated by Western blotting using an MR-specific MAb (Fig. 8C). This confirmed 
that the aldosterone-induced effects on MR distribution and SGK-1 expression were 
a consequence of PKD1 coupled signalling events, and not through non-specific 
transcriptional effects on total receptor abundance, which would determine the 
sensitivity of the cells to aldosterone treatment. 
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DISCUSSION 
Aldosterone plays a key role in regulating whole body electrolyte homeostasis, and 
the distal nephron is the pre-eminent site for endocrine regulation of Na+ efflux from 
the body. Under the influence of circulatory aldosterone levels, Na+ is reabsorbed at 
the luminal or apical surface of the ASDN principal epithelial cells from the renal 
ultra-filtrate through the ENaC and the Na+/Cl- co-transporter. The membrane 
transporters implicated directly and indirectly at each stage of the Na+ conservation 
process are regulated by aldosterone at the transcriptional level over a number of 
hours after treatment with the hormone (1). The abundance of ENaC at the apical 
surface of the principal cells of the CCD and other sections of the ASDN is the ratelimiting 
factor in affecting Na+ re-absorption in the distal nephron. However, a role for 
the earliest rapid signalling responses stimulated by aldosterone in the CCD in 
promoting Na+ transport has been unclear. This is essentially because the detection 
of increased ENaC activity in cell culture models, through the measurement of ISC, 
occurs much later than the measurable effect of aldosterone on the ionic composition 
of the renal ultra-filtrate from in vivo experiments would predict (29). The 
redistribution of pre-expressed ENaC has been linked to changes in SGK-1 
expression within 1 h of aldosterone treatment, and the earliest changes in SGK-1 
expression using a relatively physiological concentration of aldosterone (10 nM) was 
30 min after hormone treatment (30). The earliest changes in ENaC activity 
described in the literature are detected within 5 min of aldosterone treatment (8, 29), 
and must depend upon signalling events not coupled to the later detected increase in 
SGK-1 abundance. 
Functional ENaC is a heterotrimer that assembles in the endoplasmic reticulum, 
where the subunits undergo N-linked glycosylation; further posttranslational 
modification occurs on passage through the Golgi, this includes furin cleavage of the 
-and -subunits and the concurrent substitution of a simple, high mannose 
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glycosylation pattern for a complex one. The glycosylation and proteolytic processing 
of the ENaC channel are prerequisite for its full activity; however, partially processed 
or immature ENaC subunits are also associated with the cell membrane (31). Under 
high Na+ conditions ENaC is found in vesicles throughout the cytoplasm of CCD 
cells, and Na+ depletion or aldosterone exposure result in translocation of the ENaC 
vesicular pool to the apical cell membrane well in advance of ENaC subunit 
transcriptional changes (32). Changes in the rate of membrane integration of ENaC 
may be a mechanism for aldosterone-induced, signal transduction cascades to 
impact upon ENaC activity, so augmenting the transcriptional effects of MR. 
The activation of protein kinase signalling cascades has been implicated in ENaC 
activation; PKA regulates Nedd4-2 ubiquitin ligase in response to vasopressin, to 
promote ENaC activation 5 to 15 min after treatment (33). PKC has been implicated 
in the direct phosphorylation of each of the ENaC subunits, and also to increase 
channel activity in response to insulin in A6 cells (34). In apparent contradiction to 
this effect, the activation of a negative feedback pathway involving PKC and ERK1/2 
to suppress ENaC activity through enhanced proteasome degradation of the ENaC
subunit has been described in the same cell line treated with phorbol ester for >1 h 
(35). The same group described a signalling crosstalk mechanism involving ERK1/2 
and PI3-K pathways following aldosterone treatment; where PI3-K activation 
promoted ENaC activity through SGK-1, while ERK1/2 activation had a suppressive 
effect on ENaC activity (36). In this model the activation of ERK1/2 is mediated 
through elevated expression of its upstream regulator, the small G-protein K-RasA, 
which is detected 1 h after aldosterone treatment rather than a rapid response within 
minutes of treatment (36). Thus early ENaC activity is stimulated by aldosterone 
through the transcriptional regulation of SGK-1 and K-RasA. The K-RasA polypeptide 
is also methylated in response to aldosterone in A6 cells and activation of ENaC is 
sensitive to protein methylation blockade (37, 38). There is therefore the potential for 
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rapid activation of ENaC following Ras activation perhaps through a Raf-1/ERK1/2 
pathway. 
The endocrine modulation of sub-cellular trafficking is a developing field and the 
activation of signalling intermediates by aldosterone, such as PKD1 that is involved in 
vesicular trafficking, may be an important facet of this hormones activity (13). The 
activation of PKD1 at the TGN results in its persistence at this organelle, rather than 
shuttling to the nucleus; which is the response generally observed in response to cell 
membrane-associated PKD1 activation. Through its TGN association, PKD1 has 
been implicated in modulating intracellular trafficking, by regulating the fission of 
vesicles from the TGN (16, 18, 39). The precise mechanism for this is unclear; 
evidence points to significance in the interaction of PKD with the TGN-associated 
kinase PI-4 kinase III-(16). The activation of PKD1 in response to aldosterone 
coincides temporally with early changes in ENaC subunit redistribution that was 
observed in a previous study (21). Rapid surface translocation and increased ENaC 
activity has been reported in response to other agonists; for example, forskolin 
induced a two-fold increase in amiloride sensitive ISC after 25 min of treatment in a 
CCD cell line, with a simultaneous increase in surface exposure of ENaC subunits 
(40). 
In this present study, aldosterone induced a measurable increase in ENaC activity in 
the M1-CCD cells 2 to 4 h after hormone treatment that was maximal after 16 to 24 h, 
and which coincided with the sub-cellular redistribution of ENaC. We observed that 
ENaCwas expressed at higher basal levels in PKD1 suppressed cells than in wildtype 
cells; ENaCdid not become inserted into the apical membrane after 
aldosterone treatment, instead ENaCremained most abundant at the basolateral 
surface. This indicated that the process of trafficking ENaCto the apical membrane 
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was defective in PKD1 suppressed cells. Insertion of ENaC into the apical membrane 
is prerequisite for its ubiquitination and retrieval to the sub-apical pool, or to the 
proteasome for degradation. Ubiquitination of ENaC subunits requires the Ca2+- 
dependent translocation of Nedd4-2 to the apical membrane (41). A failure of PKD1- 
dependent ENaC trafficking to the apical membrane, therefore results in an increase 
in total ENaC abundance without an increase in channel activity. The PKD family 
isoforms have different roles in establishing the structure of the Golgi and regulating 
the TGN to membrane trafficking; PKD2 and PKD3 kinase-dead mutants caused 
TGN tubulation and inhibited TGN to membrane transport in a non-polarized cell 
monolayer. In the same study, PKD2 was implicated in basolateral membranespecific 
vesicle trafficking in a polarized epithelium (42). 
In addition to the sub-cellular trafficking effects, the activation of PKD1 has also been 
implicated in the regulation of gene expression, through the phosphorylation of 
transcription factors and their regulating kinases. PKD1 phosphorylates IKK to 
promote NFB-dependent transcription in response to oxidative stress (26), PKD1 
phosphorylates cJun to suppress its transcriptional activity in response to EGF (43) 
and PKD isoforms stabilize ERK1/2 activity to promote cell growth (27, 44). ERK1/2 
activation is the most frequently described signalling response to aldosterone (45, 
46), and the stabilization of ERK1/2 activation by aldosterone is also PKD1- 
dependent (47). Oestrogen promotes ERK1/2 activation, and activated ERK1/2 
phosphorylates oestrogen receptor at Ser118, to promote its nuclear localization 
(28). In this present study we found that activation of the ERK1/2 signalling cascade 
was also necessary to stabilize the association of MR with the cell nucleus following 
aldosterone treatment, suggesting a mechanism of nuclear localization that is 
common to diverse nuclear steroid receptors. Suppression of PKD1 expression 
inhibited the association of MR with the nucleus. This observation demonstrates a 
role for PKD1 not only in determining the localization of pre-expressed ENaC through 
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the regulation of vesicle trafficking, but also promoting aldosterone-stimulated gene 
expression by stabilizing the association of MR with the nucleus in combination with 
ERK1/2. The activation of PKD1 by aldosterone is an integration point between the 
rapid signalling events stimulated by the hormone, and the latent transcriptional 
events directed by MR. PKD1 is part of a cascade that integrates the cell signalling 
and transcriptional effects of aldosterone to modulate renal physiology. 
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FIGURE LEGENDS 
Fig. 1. Aldosterone-induced ENaCtranslocation is PKD1-dependent. Wild-type 
M1-CCD cells or cells suppressed in PKD1 expression were grown on cover slips 
until confluent then serum starved for 24 h. Cells were then either left untreated or 
treated with 10 nM aldosterone for 24 h (A). Cells were fixed using 4% 
paraformaldehyde. ENaCwas detected by immuno-fluorescence (green) and 
polymerized actin was stained with TRITC conjugated to phalloidin (red). Cells were 
visualized using a Zeiss LSM 510 Meta confocal microscope with excitation 
wavelengths of 488 nm (Alexa488) and 543 nm (TRITC). Images are representative 
of XY planes at indicated levels through the epithelium. The apical (a) and 
basolateral (b) surfaces of the epithelium are indicated. ZX planes through the 
stained monolayer with apical surface indicated (arrow) are also shown (B). 
Fig. 2. Aldosterone-induced ENaCapical membrane insertion is PKD1- 
dependent. Wild-type M1-CCD cells or cells suppressed in PKD1 expression were 
grown on cover slips until confluent then serum starved for 24 h. Cells were then 
either left untreated or treated with 10 nM aldosterone for 24 h. The cell membrane 
was stained with wheat germ agglutinin conjugated to Alexa546 (red) and cells were 
fixed using 4% paraformaldehyde. ENaCwas detected by immunofluorescence 
using a specific antibody and an Alexa488 conjugated secondary conjugate (green). 
Cells were visualized using a Zeiss LSM 510 Meta confocal microscope with 
excitation wavelengths of 488 nm (Alexa488) and 543 nm (Alexa546). Images are 
representative of YZ plane through the epithelium. Co-localization of ENaCwith the 
apical membrane (yellow) is indicated (arrows). 
Fig. 3. Aldosterone stimulation of the amiloride-sensitive ITE is PKD1- 
dependent. Wild-type M1-CCD cells or cells suppressed in PKD1 expression were 
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seeded (1x105 cells per support) onto semi-permeable supports in normal culture 
medium containing dexamethasone (1 M). The cells were allowed to grow with 
culture medium changes every two days and trans-epithelial electrical resistance 
(RTE) was measured each day (A). Wild-type M1-CCD cells or cells suppressed in 
PKD1 expression were seeded (1x105 cells per support) onto semi-permeable 
supports in normal culture medium containing dexamethasone (1 M). The cells 
were allowed to grow with culture medium changes every two days. Once each 
support had reached high RTE (> 800 ) medium was replaced with serum free 
containing dexamethasone for 6 h. The epithelia were then treated with 10 nM 
aldosterone or left untreated and the RTE and trans-epithelial potential difference 
(VTE) were measured at the indicated time points (B). Amiloride was added to 
determine the contribution of ENaC. The trans-epithelial current (ITE) was calculated 
using Ohm’s law. 
Fig. 4. PKD1 suppression and MEK antagonism affects MR redistribution 2 min 
after aldosterone treatment. Wild-type M1-CCD cells and M1-CCD cells 
suppressed in PKD1 expression were grown on cover slips in growth medium 
containing serum until fully confluent then grown in serum free medium for 24 h. Cells 
were then either pretreated with PD98059, treated with 10 nM aldosterone for 2 min 
or left untreated as indicated. Cells were fixed using 4% paraformaldehyde, the subcellular 
distribution of MR was determined by immunofluorecence using a MRspecific 
monoclonal antibody and detected using a murine IgG-specific antibody 
conjugated to Alexa 488 (green). The cell nuclei were counter stained with DAPI 
(red). Cells were visualized using a Zeiss LSM 510 Meta confocal microscope with 
excitation wavelengths of 488 nm (Alexa 488) and 364 nm (DAPI). Images are 
representative of a single XY focal plain mid-section through the epithelium. 
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Fig. 5. PKD1 suppression affects MR redistribution 30, 60, 120 min after 
aldosterone treatment. Wild-type M1-CCD cells and M1-CCD cells suppressed in 
PKD1 expression were grown on cover slips in growth medium containing serum until 
fully confluent then grown in serum free medium for 24 h. Cells were then either 
treated with 10 nM aldosterone for 30, 60 or 120 min or left untreated. Cells were 
fixed using 4% paraformaldehyde, the sub-cellular distribution of MR was determined 
by immunofluorecence using a MR specific monoclonal antibody and detected using 
a murine IgG specific antibody conjugated to Alexa 488 (green). The cell nuclei were 
counter stained with DAPI (red). Cells were visualized using a Zeiss LSM 510 Meta 
confocal microscope with excitation wavelengths of 488 nm (Alexa 488) and 364 nm 
(DAPI). Images are representative of a single XY focal plain mid-section. 
Fig. 6. Aldosterone-induced MR translocation is ERK1/2-dependent at 30 min. 
M1-CCD cells were grown on cover slips in growth medium containing serum until 
fully confluent then grown in serum free medium for 24 h. Cells were pre-treated with 
the MEK antagonist PD98059 (1 M). Cells were then either treated or left untreated 
with 10 nM aldosterone for 30 min. Cells were fixed using 4% paraformaldehyde, the 
sub-cellular distribution of MR was determined by immunofluorecence using a MR 
specific monoclonal antibody and detected using a murine IgG specific antibody 
conjugated to Alexa 488 (green). The cell nuclei were counter stained with DAPI 
(red). Cells were visualized using a Zeiss LSM 510 Meta confocal microscope with 
excitation wavelengths of 488 nm (Alexa 488) and 364 nm (DAPI). Images are 
representative of a single XY focal plain mid-section. 
Fig. 7. PKD1 and ERK1/2 activation promote MR nuclear localization in 
response to aldosterone. Nuclear and cytoplasmic fractions were prepared from 
M1-CCD cells and cells suppressed in the expression of PKD(-) after the indicated 
times of aldosterone treatment. Western blots were performed on the sub-cellular 
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fractions to determine the re-distribution of MR following treatment. A laminin specific 
antibody was used to confirm the efficacy of fractionation. The involvement of the 
MEK/ ERK cascades was determined by pre-incubation with PD98059. The gel 
images are representative of three independent experiments. 
Fig. 8. PKD1 involvement in aldosterone-induced gene expression. Lysates 
were prepared from wild-type M1-CCD cells and M1-CCD cells suppressed in PKD1 
expression (PKD -) either treated with aldosterone (10 nM) for 4 h (+), vehicle treated 
for 4 h (-) or not treated (0). Equivalent amounts of protein were separated on a SDSPAGE 
gel (80 g protein) then Western blotted and probed using a SGK-1 specific 
antibody (A) an ENaCspecific antibody (B) and a MR specific antibody (C). Equal 
loading was confirmed by re-probing membranes for -actin expression and the 
images shown are representative of three independent experiments. 
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